| 汪刚,郝晓宇,王双乐.化瘀解毒汤联合痰热清注射液治疗毒热证脓毒症的疗效及预后研究[J].安徽医药,2025,29(10):2101-2105. |
| 化瘀解毒汤联合痰热清注射液治疗毒热证脓毒症的疗效及预后研究 |
| Study on the efficacy and prognosis of Huayu Jiedu decoction combined with Tanreqing injection in the treatment of toxic-heat syndrome of sepsis |
| |
| DOI：10.3969/j.issn.1009-6469.2025.10.038 |
| 中文关键词: 脓毒症 热毒证 化瘀解毒汤 痰热清注射液 C反应蛋白( CRP) 肿瘤坏死因子 α 序贯器官衰竭评估(SOFA) 预后 |
| 英文关键词: Sepsis Heat-toxin syndrome Huayu Jiedu decoction Tanreqing injection C-reactive protein (CRP) Tumor ne-crosis factor α Sequential organ fai-lure assessment(SOFA) Prognosis |
| 基金项目:中国中医科学院科技创新工程项目( CI2021A02909) |
|
| 摘要点击次数: 34 |
| 全文下载次数: 34 |
| 中文摘要: |
| 目的观察分析化瘀解毒汤联合痰热清注射液治疗毒热证脓毒症的疗效及对预后的影响。方法选取北京中医药大学房山医院自 2020年 1月至 2022年 9月收治的 160例脓毒症病人按照随机数字表法分为对照组(80例)和观察组(80例)，在常规治疗的基础上，对照组给予痰热清注射液 20 mL(注入 0.9%氯化钠溶液)静脉滴注，每日 1次；观察组在对照组基础上加服化瘀解毒汤治疗，每日 1剂，水煎，早晚分服。两组疗程均为 1周。比较两组中医证候积分、临床疗效、血清 C反应蛋白(CRP)、肿瘤坏死因子 α(TNF-α)、白细胞计数、序贯器官衰竭评估(SOFA)、急性生理学和慢性健康状况评价 Ⅱ(APACHEⅡ)。结果观察组治疗后中医证候积分、 CRP、TNF-α、白细胞计数低于对照组，差异有统计学意义(P<0.05)；观察组治疗后 SOFA［(5.46±1.25)分］低于对照组［(7.84±1.65)分］APACHEⅡ评分［(10.84±1.43)分］低于对照组［(13.65±2.47)分］差异有统计学意义(P<0.05)。与对照组主要疗效(77.50%)比较，观，察组主要疗效(90.00%)较高，与对照组次要疗效(73.75%)比较，观，察组次要疗效(88.75%)较高，差异有统计学意义(P>0.05)。结论化瘀解毒汤联合痰热清注射液能够减轻毒热证脓毒症病人炎症反应、改善预后，疗效较好。 |
| 英文摘要: |
| Objective To observe and analyze the therapeutic effect of Huayu Jiedu decoction combined with Tanreqing injection on sepsis heat syndrome and its influence on prognosis.Methods A total of 160 patients with sepsis admitted to Fangshan Hospital of Bei-jing University of Chinese Medicine from January 2020 to September 2022 were selected and divided into control group (80 cases) and ob-servation group (80 cases) according to random number table method. On the basis of conventional treatment, the control group was given20 mL Tanreqing injection (injected 0.9% sodium chloride injection) intravenously, once a day. Observation group was treated with Hua. yu Jiedu decoction on the basis of the therapy of the control group, 1 dose a day, decocted in water, and to be taken morning and evening.The treatment course of both groups was 1 week. TCM symptoms score, clinical efficacy, serum C-reactive protein (CRP), tumor necrosis factor-α (TNF-α), white blood cell count (WBC), sequential organ failure assessment (SOFA), acute physiology and chronic health evalua-tion Ⅱ (APACHEⅡ) were compared between the two groups.Results The TCM syndrome score, CRP, TNF-α and WBC in the observa-tion group were lower than those in the control group after treatment, and the differences were statistically significant (P < 0.05). Aftertreatment, SOFA [(5.46±1.25) points] in the observation group was lower than that in the control group [(7.84±1.65) points], APACHEⅡscore [(10.84±1.43) points] in the observation group was lower than that in the control group [(13.65±2.47) points], and the difference wasstatistically significant (P < 0.05). Compared with the main efficacy of the control group (77.50%), the main efficacy of the observationgroup (90.00%) was higher; compared with the secondary efficacy of the control group (73.75%), the secondary efficacy of the observationgroup (88.75%) was higher, and the difference was statistically significant (P > 0.05). Conclusion Huayu Jiedu decoction combined with Tanreqing injection can reduce the inflammatory reaction and improve the prognosis of sepsis patients, whose curative effect is good. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
